
For pharmaceutical deformulation, it often involves the identification, quantification, and characterization of active pharmaceutical ingredients and all the excipients, both in the core and coating of a drug formulation[1]. Deformulation makes use of physicochemical analysis tools to characterize, from the chemical point of view, the components integrating medicine pharmaceutical formulations and from the physical point of view, the morphological part of the pharmaceutical formulation. The project is of undeniable importance, since it is useful for developing generic drugs that meet bioequivalence requirements, identifying presumed counterfeit drugs, and other aspects related to drug development. While pharmaceutical deformulation may not seem very complicated, performing it in a lab can be very time consuming and complex. For many companies in the pharmaceutical industry, finding a specialist company that can perform this service effectively is critical. Alfa Chemistry has extensive experience in pharmaceutical deformulation and has completed the deformulation services for hundreds of drugs with different forms. We look forward to being your strategic partner.
Why Do You Need Deformulation Service?
In today's highly competitive pharmaceutical landscape, deformulation has evolved from a niche analytical service into a strategic imperative across the entire drug development lifecycle. Whether you are developing generic drugs, innovating new formulations, or protecting intellectual property, pharmaceutical deformulation provides the foundational knowledge needed to make informed decisions.
- Generic drug development: Deformulation is the essential first step in the generic drug development pathway. By fully characterizing the reference listed drug (RLD), including its API form, excipient composition, and physical properties, manufacturers can design bioequivalent formulations that meet regulatory requirements under abbreviated new drug applications (ANDAs).
- Bioequivalence support: Understanding the complete formulation of a reference product is critical for demonstrating bioequivalence. Deformulation reveals critical quality attributes (CQAs) of the RLD, including particle size distribution, polymorphic form, dissolution profile, and excipient functionality, enabling generic developers to design formulations that achieve therapeutic equivalence.
- Quality control: Analysis of product composition and concentration levels to ensure consistent quality across batches, identify batch-to-batch variations, and verify raw material consistency.
- Regulatory compliance: Comply various regulatory guidelines. Deformulation results provide valuable information for DMF filings, regulatory submissions, and demonstrating compliance with pharmacopoeial standards.
- Intellectual property protection: In the competitive pharmaceutical industry, protecting your unique formulation is crucial. Deformulation can identify potential patent infringements, support patent challenges, and provide evidence for trade secret litigation.
- Complex formulation optimization: For complex drug products such as liposomal injectables, PLGA microspheres, and amorphous solid dispersions, deformulation provides deep insights into formulation architecture, enabling targeted optimization and troubleshooting.
Meet Our Services
The typical deformulation projects we undertake include, but are not limited to:
- Development of generic drug products, including full RLD characterization for ANDA filings.
- Identification of batch-to-batch variations and root cause analysis for manufacturing deviations.
- Patent infringement or trade secret investigations.
- Assessing and verifying the compliance of substances used in a pharmaceutical product compared to an SDS.
- Characterization and investigation of competitive products for strategic R&D planning.
- Comparative analysis of "good" and "bad" samples for quality troubleshooting.
- Improvement of an underperforming formulation through targeted reformulation.
- Bioequivalence risk assessment through pre-formulation deformulation analysis.
We can offer pharmaceutical deformulation service for many prescription drugs, over the counter (OTC) drugs. They can be different formulation types, for example:
- Gels
- Lotions
- Suspension
- Inhalers
- Emulsifiable granules
- Oil-miscible liquids
- Creams
- Tablet
- Controlled release products
- Suppositories
- Emulsifiable powders
- Injectable liposomal formulations
- Powders
- Ointments
- Capsule
- Solutions
- Granules
- Injectable PLGA microspheres
Even for the most complex drug formats such as injectable liposome drugs, injectable PLGA microsphere drugs and injectable nanoparticle drugs can be deformulated by Alfa Chemistry, providing critical insights for generic development and formulation optimization.
We offer two different types of pharmaceutical deformulation services to help you complete your project research:
Some products are so complex that completely deformulate may not be cost-effective. For complex products, we can provide services to identify and quantify the major ingredients of the drug to gather critical information. This procedure we call a partial deformulation. The service is typically used to verify label claims and/or determine the ingredients specified by the customer.
The service can identify and quantify all ingredients in pharmaceutical formulation. It mainly includes three main contents: (1) the identification of excipients, especially the identification of key excipients including solvents and dissolution regulators of BCS Class II or BCS Class IV drugs, wetting agents of hydrophobic drugs, pH regulators/buffers of pH sensitive drugs, and stability/antioxidant agents in readily oxidized and degraded drug formulation; (2) Separation/extraction of excipients and quantitative detection of excipients; (3) Solid state characterization of API, which may include rheology, particle size distribution, polycrystalline type, and crystallinity.
Deformulation for Generic Drug Development
Generic drug development represents one of the most significant applications of pharmaceutical deformulation. The pathway from identifying a reference product to launching a bioequivalent generic involves multiple critical steps where deformulation plays an indispensable role.
- RLD characterization: Complete chemical and physical characterization of the reference listed drug, including API identification, polymorph screening, excipient mapping, and quantitative composition analysis.
- QTPP and CQA establishment: Deformulation data directly informs the Quality Target Product Profile (QTPP) and identifies Critical Quality Attributes (CQAs) for the generic product, ensuring alignment with the RLD.
- Reverse engineering of formulation: Comprehensive identification of the formulation strategy used in the RLD, including dissolution mechanism, release control technology, and stabilization approach.
- Excipient functionality assessment: Understanding the functional role of each excipient in the RLD formulation enables rational selection of excipients for the generic product, reducing development time and regulatory risk.
- Bioequivalence strategy development: Deformulation data helps identify potential bioequivalence risks early in development, allowing formulation scientists to design appropriate strategies for BE demonstration.
- Regulatory submission support: Detailed deformulation data strengthens the quality overall summary (QOS) and provides justification for formulation decisions in ANDA submissions.
Bioequivalence: The Role of Deformulation
Bioequivalence (BE) is the cornerstone of generic drug approval. The ability to demonstrate that a generic product performs equivalently to the reference product in terms of rate and extent of absorption depends critically on understanding the reference product's formulation architecture. Pharmaceutical deformulation provides the analytical foundation for BE strategy development.
At Alfa Chemistry, our deformulation approach for BE support encompasses the following key dimensions:
- Comparative dissolution profiling: Identifying the dissolution mechanism of the RLD through deformulation enables the design of generic formulations with matching dissolution profiles, a critical prerequisite for BE.
- Polymorph and solid-state characterization: Different polymorphic forms of the same API can exhibit different solubility and bioavailability. Deformulation identifies the exact polymorph used in the RLD, ensuring the generic product uses the appropriate form.
- Particle size and surface area analysis: For BCS Class II and IV drugs, particle size directly impacts dissolution rate and bioavailability. Deformulation quantifies critical particle attributes of the RLD.
- Excipient compatibility and functionality: Key excipients in the RLD formulation may serve critical functions for bioavailability enhancement. Deformulation identifies these functional excipients and their concentrations.
- BE risk assessment: By identifying potential sources of bioinequivalence early through comprehensive deformulation, developers can mitigate formulation risks before costly clinical studies.
- IVIVC development support: Deformulation data supports the development of in vitro-in vivo correlations (IVIVC), potentially enabling biowaivers for certain formulation changes.
Complex Formulation Case Studies
Alfa Chemistry has successfully completed deformulation projects for a wide range of complex pharmaceutical formulations. Below are representative examples demonstrating the depth and breadth of our capabilities.
Case Study 1: Injectable Liposomal Formulation
Challenge: A generic pharmaceutical company needed to develop a bioequivalent version of a proprietary liposomal injectable drug. The RLD contained a complex lipid bilayer system with multiple phospholipids, cholesterol, and a remote loading mechanism for the active ingredient.
Solution: Alfa Chemistry employed a multi-technique deformulation approach including HPLC-MS for lipid profiling, cryo-TEM for vesicle morphology characterization, dynamic light scattering for particle size distribution, and ICP-MS for trace element analysis. The complete lipid composition, including the ratio of hydrogenated soy phosphatidylcholine to cholesterol and the presence of PEGylated lipids, was accurately quantified.
Outcome: The client received a comprehensive formulation report including quantitative lipid composition, internal aqueous phase chemistry, and drug loading efficiency data. This information directly enabled the design of a liposomal formulation that matched the RLD's critical quality attributes, supporting a successful ANDA submission.
Case Study 2: Controlled-Release Tablet Formulation
Challenge: A pharmaceutical company sought to understand the formulation strategy behind a once-daily controlled-release tablet product that used a combination of hydrophilic and hydrophobic matrix formers to achieve a 24-hour release profile.
Solution: Alfa Chemistry applied a tiered deformulation strategy: FTIR and Raman spectroscopy for rapid polymer identification, NMR for quantitative analysis of the matrix-forming agents, SEM-EDS for tablet microstructure analysis, and dissolution testing under multiple pH conditions to characterize the release mechanism.
Outcome: The deformulation revealed a sophisticated matrix system combining hydroxypropyl methylcellulose (HPMC) with ethylcellulose, along with a pH-modifying agent to maintain consistent release across the GI tract. The client successfully replicated the release profile using our formulation insights.
Case Study 3: Complex Ophthalmic Emulsion
Challenge: A specialty generic developer needed to reverse engineer a patented ophthalmic emulsion containing a poorly water-soluble API stabilized by a complex surfactant system.
Solution: Alfa Chemistry utilized LC-MS/MS for API and preservative quantification, GC-MS for volatile component identification, droplet size analysis, zeta potential measurement, and rheological characterization to fully understand the emulsion's stabilization mechanism.
Outcome: The deformulation identified the specific surfactant blend, oil phase composition, and tonicity adjustment strategy used in the RLD. The client was able to design a Q1/Q2 equivalent formulation, significantly reducing the regulatory pathway to market.
Our deformulation services are more than just identifying and quantifying ingredients. Our team of experienced pharmaceutical scientists works closely with clients to translate analytical data into actionable formulation strategies, whether for generic development, formulation optimization, or competitive intelligence. Please contact us today to discuss your project.
Techniques and Instruments
Alfa Chemistry uses various techniques and instruments for pharmaceutical deformulation, including but not limited to:
How We Proceed?

Frequently Asked Questions
Q: How does deformulation support generic drug development?
A: Deformulation is the foundational step in generic drug development. By fully characterizing the reference listed drug, including API identity and polymorph form, quantitative excipient composition, and critical physical properties, deformulation provides the essential data needed to design a bioequivalent formulation. This information directly supports QbD-based formulation development and ANDA submissions.
Q: What is the minimum sample size required for pharmaceutical deformulation?
A: The required sample size varies depending on the formulation complexity. For standard tablets and capsules, 5-10 dosage units are typically sufficient. For complex formulations such as injectable liposomes or controlled-release systems, 10-20 dosage units may be required. Our scientists will advise on the specific sample requirements for your project.
Q: Can deformulation help with bioequivalence studies?
A: Yes, deformulation plays a critical role in bioequivalence strategy development. By identifying the critical quality attributes of the reference product, including particle size distribution, polymorphic form, dissolution profile, and excipient functionality, deformulation enables the design of generic formulations that achieve therapeutic equivalence. It also helps identify potential BE risks before costly clinical studies.
Q: What types of complex formulations can Alfa Chemistry analyze?
A: Alfa Chemistry has extensive experience with a wide range of complex formulations, including liposomal injectables, PLGA microspheres, nano-suspensions, amorphous solid dispersions, controlled-release tablets, ophthalmic emulsions, transdermal patches, and inhalable formulations. Our multi-technique analytical platform enables comprehensive characterization of even the most challenging drug delivery systems.
Q: How long does a typical pharmaceutical deformulation project take?
A: Project timelines depend on formulation complexity. Standard projects for conventional tablets or capsules are typically completed within 2-4 weeks. Complex formulations, such as liposomal injectables or controlled-release systems, may require 4-8 weeks. We offer expedited timelines for urgent projects upon request.
Q: Are the deformulation results confidential?
A: Absolutely. All project information, analytical data, and results are treated as strictly confidential. Alfa Chemistry is happy to sign a non-disclosure agreement (NDA) before project initiation. Our confidentiality protocols ensure that your proprietary formulation information is fully protected.
Please kindly note that our products and services are for research use only.